Cystamine-d8 (hydrochloride) |
| Catalog No.GC47160 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2712126-51-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cystamine-d8 (hydrochloride) is intended for use as an internal standard for the quantification of cystamine by GC- or LC-MS. Cystamine is an organic disulfide that inhibits tissue transglutaminase (TGM2) with an IC50 value of approximately 2.5 mM.1 It is orally available and is neuroprotective in mouse models of Huntington's disease.2,3 Cystamine also inhibits caspase-3, increases intracellular glutathione, and reduces inflammation in a rat model of inflammatory bowel disease.4
1.Smethurst, P.A., and Griffin, M.Measurement of tissue transglutaminase activity in a permeabilized cell system: Its regulation by Ca2+ and nucleotidesBiochem. J.313(pt 3)803-808(1996) 2.Dedeoglou, A., Kubilus, J.K., Jeitner, T.M., et al.Therapeutic effects of cystamine in a murine model of Huntington's diseaseJ. Neurosci.22(20)8942-8950(2002) 3.Borrell-PagÈs, M., Canals, K.P., CordeliÈrs, F.P., et al.Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminaseJ. Clin. Invest.116(5)1410-1424(2006) 4.Elli, L., Ciulla, M.M., Busca, G., et al.Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel diseaseLab. Invest.91(3)452-461(2011)
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *